Biophan Technologies, Inc

Biophan Technologies, Inc.

Company Overview and Update

The Wall Street Analyst Forum – 16th Annual Analyst Conference

March 2, 2005

Michael Weiner, CEO

Biophan Technologies, Inc. (OTCBB: BIPH)

Biophan’s Mission

Enable over $12 billion worth of medical devices shipping annually safe for use with MRI, and imageable. Many are not: Guidewires, catheters, endoscopes, biopsy needles Pacemakers, defibrillators, neurostimulators, drug

pumps (safety issues, also imaging issues), pain control devices

Stents, embolism clips, aneurysm clips, artificial hips, knees, most other orthopedics

Bring other innovations for competitive advantage to biomedical device and pharmaceutical companies.


Summary Financial Information

Share Price (02.28.05): $1.55 52-Week High: $1.55 52 Week Low: $0.46 Shares Outstanding: 74 million Float: 58 million Market Cap: $114.7 million Average Daily Volume: 510,454

BIOPHAN (OTC: BIPH)

http://edit.finance.yahoo.com/e5a?.vk=s&.intl=us&.done=http://finance.yahoo.com/q?s=biph.ob


Biophan’s Solutions

MRI Safety: (many products contraindicated) RF filter from Johns Hopkins (heating) Biophan multi-filar wire solution (heating) “Anti-Antenna” lead design (induced voltages)

Image Compatibility Nanomagnetic particle thin film coatings (Nanoset, LLC

and Alfred University) Minimize image artifacts Makes catheters, guidewires, stents, and devices visible

under MRI


Management

Stu MacDonald, VP R&D at J&J division, with a 400 person organization

Jeff Helfer, VP Engineering – formerly Dir. Of Engineering at the same J&J division

John Lanzafame, President, Nanolution Division – former President STS Biopolymers, acquired by Angiotech (ANPI)

Robert Wood, VP Finance, Treasured and CFO, CPA in public and private firms

And now Dr. Michael Friebe, and Dr. Andreas Melzer, two well known leaders in MRI technologies


Biophan-Europe

Acquired February, 2005, AMRIS (now Biophan Europe) adds enormous additional capability to Biophan

2 Ph.D. level MRI experts, Friebe and Gregor MD, surgeon and inventor, Andreas Melzer, MD Access to latest MRI devices Excellent connections in the MRI community Exciting, patented solutions


Core Business

Offering our customers competitive advantage Through proprietary solutions that can gain

marketshare for them FDA approval is pursued by the customer Marketing and distribution of the final device is

theirs We sell high margin components and develop

annuities for our shareholders


Relationship With Boston Scientific

Joint development agreement, originally entered into November, 2003

Recently moved to second and third phase, and has expanded to multiple products

One of the companies referred to in recent 10Q Reached agreement on term sheet, working on

final contract phase

MRI Device Imaging

SE coronal image of 3 aluminum wires (1/32”). Wire (3) is uncoated.

1 2 3

Biophan’s thin-film

nanomagnetic particle

coating technology

provides a controllable,

“magnetic” signal

capable of creating an

image of the coated

device.

#3 is uncoated.


Making Stents Imageable

Seeing blockage of stents has required an invasive procedure

Stents imageable under MRI would be competitively advantaged

Biophan’s business is competitive advantage for our customers through technology innovation

Nanoset has a coating solution AMRIS, now Biophan-Europe, has a “retrofit” solution Both solutions are PATENTED! Together we “cover the waterfront”


Implications

Impact the $5+ billion stent market Help manufacturers make pacemakers,

defibrillators, neurostimulators safe, and imageable – competitive advantage to our licensees

Make guidewires, catheters, endoscopes, biopsy needles safe and image compatible

Opens the field of interventional medicine under MRI (currently only X-Ray/Fluoroscopy)


Biothermal Battery

Goal: To provide a long-lived electrical power system for implanted medical devices Powered by body heat differential.

Acquired 51% interest in TE-Bio, which holds an issued U.S. patent for the battery

Batteries are a $500 million market, sell for $100 to $225 each in the pacemaker, defibrillator and drug pump markets

Sold to same customers who need MRI safety


Agreement with NASA

Announced on August 17th a deal with NASA Ames Research Center for Nanotechnology to jointly develop the biothermal battery NASA wants technology for their long duration

manned MARS mission for biosensing and miniature therapeutic devices

Biophan gets commercial rights to jointly developed and NASA developed technology

Nanotechnology and materials science advances makes the biothermal battery possible


Substrate

Polymer Coating

Nanomagnetic layer

Con

trol

led

Mag

netic

Fie

ldDrug bound to NMP carrier

Con

trol

led

Mag

netic

Fie

ld A

Con

trol

led

Mag

netic

Fie

ld B

Particle type ADrug AParticle type BDrug B

Surface Elution on Demand


Reloading Drug Eluting Coatings

Substrate

Polymer Coating

Concentration G

radient

Controlled

Magnetic F

ield

Drug Molecules

Drug bound to NMP carrier

Nanomagnetic layer


Guided Drug Delivery

Solid tumor

Apply magnetic field to concentrate particles

Modulate field to release drug from particles

Inject NMPs IV,NMP will circulate through the blood stream

Other options for targeting:1 - Direct injection into tumor site2 - Coating NMP with antibodies to target tumor


Other Solution Offerings

MRI Safe Drug Pump (non-magnetic) Nanomagnetic particles for contrast agents

Also used forMRI compatibilityReduce device heatingEnable DRUG DELIVERY CAPABILITIES!

NanoViewtm

MRI Contrast Agents

NanoViewtm

Nano-particulate technology has the potential to

provide a new consumable product capable of

significantly enhancing MR detection sensitivity

(i.e. lowest detectable concentration) and

specificity (i.e. the ability to reliably detect the

desired substance).


PROTECTED, PROTECTED!

Technologies covered by 108 U.S. Patents

33 ISSUED 75 pending or allowed

Owned by Biophan or licensed exclusively to Biophan for the medical market

Plus many International patents


Goals

Close major deal – underway, at contract phase Close second deal – we have multiple prospects

in the U.S. Europe, and Asia List on major exchange – requires $5 million

capital, we meet all other qualifications, we plan to file as soon as capital in hand


Revenue Potential for MRI Safety and Visibility (by example, not a forecast)

Customer Sales

In Billion$ Year3%

(million$ yr)

5%(million$ yr)

1 30 50

2 60 100

3 90 150

4 120 200

5 150 250

12 360 600


Sensitivities

Deal Terms Improve with: Proof of principle Issued patents (the more the better) Multiple prospects Cash in the bank Capability Capacity


Other Markets

Battery: $500 million Contrast Agents: $800 million Drug Pumps: $1 billion Drug Delivery: $40 billionCautions: Penetration can take timeFDA approval and/or CE Mark could take timeBright side is, once deal is underway, patents and

annuity streams can last a long time


Biophan (OTC: BIPH)

We don’t make medical devices; We make them safe, and imageable, for MRI

And other competitive advantages for our customers

Four of our six technologies are based on nanotechnology

WWW.BIOPHAN.COM


Thank You!

More good things will unfold in 2005!

BIOmedPHArmaNano

Technologies

Documents

Biophan Technologies, Inc